218 related articles for article (PubMed ID: 24334643)
1. Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry.
Bykerk VP; Shadick N; Frits M; Bingham CO; Jeffery I; Iannaccone C; Weinblatt M; Solomon DH
J Rheumatol; 2014 Feb; 41(2):227-34. PubMed ID: 24334643
[TBL] [Abstract][Full Text] [Related]
2. Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change.
Mahmoud TG; Huang J; Frits M; Iannaccone C; Bykerk V; Bingham CO; Weinblatt M; Shadick NA
J Rheumatol; 2020 Mar; 47(3):333-340. PubMed ID: 31203222
[TBL] [Abstract][Full Text] [Related]
3. Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors.
Goodman SM; Bykerk VP; DiCarlo E; Cummings RW; Donlin LT; Orange DE; Hoang A; Mirza S; McNamara M; Andersen K; Bartlett SJ; Szymonifka J; Figgie MP
J Rheumatol; 2018 May; 45(5):604-611. PubMed ID: 29545451
[TBL] [Abstract][Full Text] [Related]
4. The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).
Barroso N; Woodworth TG; Furst DE; Guillemin F; Fautrel BJ; Borazan N; Kafaja S; Brook J; Elashoff DA; Ranganath VK
Clin Rheumatol; 2020 Jan; 39(1):189-199. PubMed ID: 31493148
[TBL] [Abstract][Full Text] [Related]
5. Pain and Self-reported Swollen Joints Are Main Drivers of Patient-reported Flares in Rheumatoid Arthritis: Results from a 12-month Observational Study.
Kuettel D; Primdahl J; Weber U; Terslev L; Østergaard M; Petersen R; Pedersen AK; Möller S; Hørslev-Petersen K
J Rheumatol; 2020 Sep; 47(9):1305-1313. PubMed ID: 31787604
[TBL] [Abstract][Full Text] [Related]
6. Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.
Markusse IM; Dirven L; Gerards AH; van Groenendael JH; Ronday HK; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
Arthritis Res Ther; 2015 Aug; 17(1):232. PubMed ID: 26321751
[TBL] [Abstract][Full Text] [Related]
7. Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study.
Ometto F; Raffeiner B; Bernardi L; Bostsios C; Veronese N; Punzi L; Doria A
Arthritis Res Ther; 2016 Apr; 18():89. PubMed ID: 27080123
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
9. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.
Cardiel MH; Pons-Estel BA; Sacnun MP; Wojdyla D; Saurit V; Marcos JC; Pinto MR; Cordeiro de Azevedo AB; da Silveira IG; Radominski SC; Ximenes AC; Massardo L; Ballesteros F; Rojas-Villarraga A; Oñate RV; Hernandez MP; Esquivel-Valerio JA; García-De La Torre I; Khoury VJ; Millán A; Soriano ER;
J Clin Rheumatol; 2012 Oct; 18(7):327-35. PubMed ID: 23047532
[TBL] [Abstract][Full Text] [Related]
10. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey.
Bolge SC; Waters H; Piech CT
Clin Ther; 2010 Feb; 32(2):238-45. PubMed ID: 20206781
[TBL] [Abstract][Full Text] [Related]
11. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs.
Contreras-Yáñez I; Ponce De León S; Cabiedes J; Rull-Gabayet M; Pascual-Ramos V
Am J Med Sci; 2010 Oct; 340(4):282-90. PubMed ID: 20881757
[TBL] [Abstract][Full Text] [Related]
12. Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study.
Raheel S; Matteson EL; Crowson CS; Myasoedova E
Rheumatology (Oxford); 2017 Dec; 56(12):2154-2161. PubMed ID: 28968703
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
[TBL] [Abstract][Full Text] [Related]
14. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study.
Lie E; Woodworth TG; Christensen R; Kvien TK; Bykerk V; Furst DE; Bingham CO; Choy EH;
Ann Rheum Dis; 2014 Oct; 73(10):1781-7. PubMed ID: 23852690
[TBL] [Abstract][Full Text] [Related]
15. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.
Iannaccone CK; Lee YC; Cui J; Frits ML; Glass RJ; Plenge RM; Solomon DH; Weinblatt ME; Shadick NA
Rheumatology (Oxford); 2011 Jan; 50(1):40-6. PubMed ID: 20847201
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
[TBL] [Abstract][Full Text] [Related]
18. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
